Loading
Founded Biocon in a garage in 1978 and turned it into the company behind the world's first approved trastuzumab biosimilar, and co-founded a 1,400-bed cancer campus in Bengaluru.
Kiran Mazumdar-Shaw started Biocon in Bengaluru in 1978 with 10,000 rupees of seed capital and built it into India's largest biopharmaceutical company; she is executive chairperson of Biocon and Biocon Biologics, whose portfolio includes trastuzumab (CANMAb in India, 2014; Ogivri in the US, 2017) and bevacizumab biosimilars and which acquired Viatris's biosimilars business in 2022. In 2009 she established the Mazumdar-Shaw Medical Centre with Devi Shetty at Narayana Health City, a 1,400-bed cancer and multispecialty campus. She holds the Padma Shri (1989), Padma Bhushan (2005) and the Othmer Gold Medal (2014).
Shares Narayana Health (Mazumdar Shaw Medical Centre), Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care, Monoclonal antibodies.
Shares Prices and value, Most of the world has almost no cancer care, Monoclonal antibodies.
Shares Trastuzumab biosimilars, Prices and value.
Shares Biocon Biologics, Trastuzumab biosimilars.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.